Compare BCAB & PETS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCAB | PETS |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 63.7M |
| IPO Year | 2020 | N/A |
| Metric | BCAB | PETS |
|---|---|---|
| Price | $0.31 | $3.42 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 3 | 1 |
| Target Price | $1.00 | ★ $3.20 |
| AVG Volume (30 Days) | ★ 2.0M | 1.2M |
| Earning Date | 11-13-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $198,265,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.24 | $1.57 |
| 52 Week High | $1.43 | $5.58 |
| Indicator | BCAB | PETS |
|---|---|---|
| Relative Strength Index (RSI) | 26.50 | 59.87 |
| Support Level | $0.40 | $3.23 |
| Resistance Level | $0.82 | $3.70 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 0.19 | 47.36 |
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.